Googles Shweta Maniar writes about what shes learned traveling to conferences across the planet to talk about the convergence ...

Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesnt have to be that way, writes Anastasia Christianson, Ph.D.

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO Stephen Beckman.

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin testing. Charles River Labs Nicola Reid lays out the issues to consider.

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

Building iteration into the product commercialization process can help life sciences companies avoid many of the missteps that slow down adoption and stall growth, explains Jessica Meng.

AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and sufficiency of disclosure, explains patent attorney Noah K. Tilton.

The article discusses the risks of non-compliance with federal laws in sponsored genetic testing programs and offers insights from Morrison Foerster experts.